Chinese biotech dominance in R&D is on the rise
by
Contributor since / Followers
Contributor since / Followers
2 days ago
narvikk/E+ via Getty Images Against a backdrop of rising U.S.-China geopolitical tensions, there are signs
ABBV
Pharma lobby slams IRA, PBMs as Medicare lists 15 more drugs for price setting
by
Contributor since / Followers
Contributor since / Followers
3 days ago
wildpixel/iStock via Getty Images As Medicare announced a fresh set of drugs selected for its
Wegovy included as Medicare lists 15 drugs selected for next pricing negotiations
by
Contributor since / Followers
Contributor since / Followers
3 days ago
wingedwolf The Centers for Medicare and Medicaid Services (CMS) on Friday announced 15 additional Medicare
AbbVie retains Humira market share above 70%: report
by
Contributor since / Followers
Contributor since / Followers
4 days ago
vzphotos/iStock Editorial via Getty Images AbbVie (NYSE:ABBV) has managed to keep its market share for
AbbVie may commit less capital to psych drugs: report
by
Contributor since / Followers
Contributor since / Followers
5 days ago
hapabapa AbbVie (NYSE:ABBV) reportedly may commit less capital to the development of psychiatric drugs in
AbbVie goes ex dividend tomorrow
by
Contributor since / Followers
Contributor since / Followers
6 days ago
AbbVie (NYSE:ABBV) had declared $1.64/share quarterly dividend. Payable Feb. 14; for shareholders of record Jan.
AbbVie, AbCellera expand collaboration into T-cell engagers
by
Contributor since / Followers
Contributor since / Followers
1 week ago
AbbVie (NYSE:ABBV) and AbCellera (NASDAQ:ABCL) have expanded their collaboration to include the discovery of T-cell
SpringWorks Therapeutics jumps amid takeover speculation
by
Contributor since / Followers
Contributor since / Followers
1 week ago
sanjeri/E+ via Getty Images SpringWorks Therapeutics (NASDAQ:SWTX) advanced 6.3% amid takeover speculation. The biotech firm
AbbVie terminates Alector collaboration agreement
by
Contributor since / Followers
Contributor since / Followers
1 week ago
hapabapa Alector (NASDAQ:ALEC) said AbbVie (NYSE:ABBV) has sent written notice that it is terminating the
AbbVie to record $3.5B impairment charge for Cerevel drug
by
Contributor since / Followers
Contributor since / Followers
1 week ago
vzphotos/iStock Editorial via Getty Images AbbVie (NYSE:ABBV) said it expects to record an impairment charge